Mandate

Vinge advises Nuevolution in connection with a directed share issue

May 25, 2018

The board of directors of Nuevolution has resolved on a directed new issue of shares, whereby Nuevolution will raise proceeds of approximately SEK 110 million, before issue costs.

The share issue is directed to a number of selected Swedish and international investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ) and Redeye AB.

Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company’s shares are admitted to trading on Nasdaq First North Premier.

Vinge’s team has consisted of Dain Hård Nevonen, David Andersson, Malte Hedlund and Stephanie Stiernstedt.

Related

Vinge advises Consolid Equity on the sale of Road Mobility Services to Nalka

Vinge has advised Consolid Equity on the sale of Road Mobility Services to Nalka. In connection with the transaction, Consolid, entrepreneurs and management will reinvest and remain as minority shareholders alongside Nalka as the new majority shareholder.
August 28, 2026

Vinge advises IK Partners and Selatek in connection with the acquisition of Jamo Sikring

Vinge advises IK Partners and their portfolio company Selatek AB ("Selatek") in connection with the acquisition of JAMO SIKRING A/S ("Jamo Sikring"), a Danish specialist in the installation, maintenance and ongoing inspection of fire protection systems. The acquisition marks Selatek's establishment of operations in Denmark and strengthens the group's position in fire safety and security services in the Nordics.
August 21, 2026

Vinge advises Xamera Group on the acquisition of the Finnish company Integrify

Xamera Group, partly owned by Helix Kapital, has acquired all the shares in the Finnish company Integrify, a leading Finnish provider of technology-focused and hire-purchase-based skills provision to the industrial, defence and tech sectors.
August 20, 2026